Orient Technologies (NSE: ORIENTTECH) Q3 FY26 results: Why short-term margin pain may be the price of securing long-cycle government and services revenue
Read More 5 minute read Pharma Industry News N2OFF enters cancer-drug discovery market through MitoCareX merger Find out how N2OFF’s merger with MitoCareX is reshaping its business and targeting pancreatic & lung cancers! bySoujanya RaviOctober 30, 2025